Psilocybin Therapy for Psychological Distress in Palliative Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
COPD (Chronic Obstructive Pulmonary Disease)ALS (Amyotrophic Lateral Sclerosis)MS (Multiple Sclerosis)Major Depressive Disorder (MDD)Atypical Parkinson Disease
Interventions
DRUG

Psilocybin therapy

Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists

All Listed Sponsors
collaborator

HumanKindLabs

UNKNOWN

collaborator

University of Copenhagen

OTHER

collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

collaborator

OPEN Foundation

UNKNOWN

collaborator

IESE Business School

UNKNOWN

collaborator

Uppsala University

OTHER

collaborator

The Champalimaud Centre, Lisbon, Portugal

UNKNOWN

collaborator

Stockholm University

OTHER

collaborator

University of Groningen, The Netherlands

UNKNOWN

collaborator

National Institute of Mental Health, Czech Republic

OTHER

collaborator

European Association for Palliative Care (EAPC)

UNKNOWN

collaborator

Madopa

UNKNOWN

collaborator

Bispebjerg Hospital, Copenhagen, Denmark

UNKNOWN

collaborator

European Association of Neurological Associations (EFNA)

UNKNOWN

collaborator

29k International AB

UNKNOWN

collaborator

Lung Alliance Netherlands

UNKNOWN

collaborator

European Psychiatric Association

UNKNOWN

collaborator

Norrsken Mind

UNKNOWN

lead

University Medical Center Groningen

OTHER